A Phase 4 interventional study of Coronavac in SARS-CoV Infection, Coronavirus Infection and Vaccine Adverse Reaction, sponsored by Hospital do Rim e Hipertensão. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-03-18.
Sponsored by Hospital do Rim e Hipertensão · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil — 3 open to participants now, 4 under way, 2 of them phase 3. Severe Acute Respiratory Syndrome · Brazil.
Among the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2021, is the only one in phase 4, and was the 24th registered.
376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.
Browse Severe Acute Respiratory Syndrome studies →3 of the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Brazil, United States, Argentina and 36 more countries
Ages 18+
Cardresearch · Sites in Brazil
Ages 18+
D'Or Institute for Research and Education · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 2020; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,371 is above the median of 140 across 210 interventional studies indexed under Severe Acute Respiratory Syndrome.
Median enrollment 279 across the 26 interventional studies, 250 across the 3 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 29 have an industry lead sponsor. The 10 most frequent:
Hospital do Rim e Hipertensão is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Hospital do Rim e Hipertensão has 1 study filed under Severe Acute Respiratory Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Severe Acute Respiratory Syndrome with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Since the beginning of the SARS-CoV-2 pandemic, 1031 (8.7%) of the 11875 kidney transplant recipients being followed up at Hospital do Rim have been infected. The overall lethality rate was 24%, reaching 53% among those over 70 years old. Among the survivors, there is also a high incidence of renal dysfunction with loss of the renal graft and definitive return to dialysis. Patients receiving pharmacological immunosuppression, including transplant recipients, have not been included in the studies carried out to date. In addition, kidney transplant recipients may have reduced vaccine responses compared to the general population. The severity, the high incidence of renal dysfunction and loss of renal graft, and the high lethality associated with COVD-19 justify the investigation of the epidemiological impact and immunogenicity of the vaccine against SARS-CoV-2 infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Kidney transplant recipients receiving the coronavac vaccine
Biological: Coronavac
The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
Evaluate the incidence of hospitalization or death in 28 days associated with COVID-19 (symptomatic cases confirmed virologically by COVID -19 with positive CRP) 14 ± 2 days after the second dose of the vaccine.
Time frame: 45 days
Evaluate the impact of the vaccine on the incidence of COVID-19 according to the severity criterion of the World Health Organization.
Time frame: 6 months
Evaluate the impact of the vaccine on the incidence of COVID-19 and hospitalization for COVID-19 disease, confirmed by PCR, for a period of 6 months after the final vaccination.
Time frame: 6 months
Evaluate the vaccine's safety, tolerability, and reactogenicity profile: occurrence of signs and symptoms of local and systemic reactogenicity requested seven days after vaccination.
Time frame: 7 days
Evaluate the incidence of serious adverse events for a period of 6 months after the final vaccination.
Time frame: 6 months
Evaluate immunogenicity by detecting antibodies against SARS-CoV-2 for a period of 6 months after the final vaccination.
IgG antibody levels will be used to assess immunogenicity.
Time frame: 6 months
Analysis of the genetic sequencing of SARS-CoV-2 in patients who test positive for SARS-CoV-2 PCR.
Genetic sequencing of the virus will be carried out, that is, reading the genome of Sars-Cov-2, to evaluate possible new variants.
Time frame: 6 months
Plan to share: No
Ran from Mar 2021 to primary completion in Oct 2021, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sinovac COVID-19 vaccine
Severe Acute Respiratory Syndrome →
Hospital do Rim e Hipertensão